Cerus Corp (CERS) Misses Q1 EPS by 10c, Comments on Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cerus Corp (CERS) Enters INTERCEPT Blood System Agreement w/ Karolinska University Hospital
February 27, 2015 8:40 AM ESTCerus Corp (NASDAQ: CERS) announced that the Karolinska University Hospital (KUH) in Stockholm, has signed a three-year agreement to purchase the INTERCEPT Blood System for platelets. In addition to the three-year base term, the agreement allows for automatic annual extensions for an additional two years. KUH is Swedens largest platelet supplier and one of the largest University Hospitals in Europe, producing over 10,000 platelet units, or 20% of Swedens platelet... More
Cerus (CERS) PT Lowered to $6.50 at Wedbush Post Q4; 'Outperform' Maintained
February 27, 2015 7:16 AM ESTWedbush analyst Zarak Khurshid trimmed its price target on Cerus (NASDAQ: CERS) to $6.50 (from $7.50) but maintained an Outperform rating following results.
Khurshid notes, "Adjusted EPS loss roughly in-line. CERS reported 4Q14 sales of $9.7 MM and adjusted EPS loss of ($0.16), missing our $10.4 MM... More
